Moderna & merck announce 3-year data for mrna-4157 (v940) in combination with keytruda(r) (pembrolizumab) demonstrated sustained improvement in recurrence-free survival & distant metastasis-free survival versus keytruda in patients with high-risk stage iii/iv melanoma following complete resection
At a median planned follow-up of the phase 2b study at 34.9 months, mrna-4157 (v940) in combination with keytruda reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% compared to keytruda alone in these patients the 2.5-year recurrence-free survival rate of mrna-4157 (v940) in combination with keytruda was 74.8% as compared to 55.6% for keytruda alone, with the benefit observed across exploratory subgroups the companies have initiated phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer, in addition to phase 2 studies in patients with renal cell carcinoma and urothelial carcinoma and a phase 2/3 study for cutaneous squamous cell carcinoma cambridge, ma and rahway, nj / accesswire / june 3, 2024 / moderna, inc. (nasdaq:mrna) and merck (nyse:mrk), known as msd outside of the united states and canada, today announced the first presentation of results from a planned analysis from the phase 2b randomized keynote-942/mrna-4157-p201 study, a clinical trial evaluating mrna-4157 (v940), an investigational individualized neoantigen therapy (int), in combination with keytruda, merck's anti-pd-1 therapy, in patients with resected high-risk melanoma (stage iii/iv) following complete resection (n=157). with a median follow-up of approximately three years (34.9 months), adjuvant treatment with mrna-4157 (v940) in combination with keytruda continued to demonstrate a clinically meaningful and durable improvement in recurrence-free survival (rfs), the primary endpoint of the study, reducing the risk of recurrence or death by 49% (hr [95% ci], 0.510 [0.288-0.906]; two-sided nominal p-value 0.019) compared with keytruda alone.
MRNA Ratings Summary
MRNA Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission